Merck KGaA (MRK.DE)
-XETRA 125.30 
2.00(1.62%) 11:35AM EDT
| Prev Close: | 123.30 |
|---|
| Open: | 123.55 |
|---|
| Bid: | 125.40 |
|---|
| Ask: | 125.45 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 121.95 - 126.00 |
|---|
| 52wk Range: | 75.47 - 127.50 |
|---|
| Volume: | 330,028 |
|---|
| Avg Vol (3m): | 232,097 |
|---|
| Market Cap: | 27.24B |
|---|
| P/E (ttm): | 41.24 |
|---|
| EPS (ttm): | 3.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in EUR.
Headlines
- EU fines Lundbeck and others 146 mln euros for blocking rival drugsat Reuters(Wed 8:24AM EDT)
- EU fines Lundbeck, 8 others 146 mln euros for blocking cheaper drugsat Reuters(Wed 6:02AM EDT)
- Lundbeck Fined $125.6 Million by EU Drug Delay Probeat Bloomberg(Wed 5:30AM EDT)
- Analysis: After tech success, Israel seeks life sciences growthReuters(Thu, Jun 6)
- Bayer, Merck KGaA Sue Actavis Claiming Patent Violationat Bloomberg(Wed, Jun 5)
- EU regulators to impose fines on generic drug makersReuters(Mon, Jun 3)
- German stocks - Factors to watch on June 3at Reuters(Mon, Jun 3)
- Merck KGaA's Erbitux beats Avastin in bowel cancer trialat Reuters(Sat, Jun 1)
- Erbitux Tops Roche’s Avastin for Colon Cancer Survivalat Bloomberg(Sat, Jun 1)
- Swiss Billionaires Buy Merck Geneva Building for Biotech Campusat Bloomberg(Wed, May 22)
- Swiss billionaires buy Merck Serono HQ for biotech campusat Reuters(Wed, May 22)
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccineat Bloomberg(Fri, May 17)
- Oncothyreon slumps on new cancer drug dataAP(Thu, May 16)
- Merck KGAA Earnings Call scheduled for 8:00 am ET todayCCBN(Tue, May 14)
- Q1 2013 Merck KGaA Earnings Release - 01:00 am ETCCBN(Tue, May 14)
Reports
- No Reports available for MRK.DE at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.37 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Merck KGaA operates as a pharmaceutical, chemical, and life science company worldwide. It operates through four divisions: Merck Serono, Consumer Health, Performance Materials, and Merck Millipore.
View More